000 01294 a2200373 4500
005 20250518021104.0
264 0 _c20200722
008 202007s 0 0 eng d
022 _a1578-8989
024 7 _a10.1016/j.medcli.2018.11.013
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aDelgado Sánchez, Olga
245 0 0 _aBiosimilar medicines: impact, opportunities and strategies. Twelve years of experience in Europe.
_h[electronic resource]
260 _bMedicina clinica
_c05 2019
300 _a411-415 p.
_bdigital
500 _aPublication Type: Journal Article; Review
650 0 4 _aAttitude
650 0 4 _aBiosimilar Pharmaceuticals
_xeconomics
650 0 4 _aCost Control
650 0 4 _aDrug Approval
650 0 4 _aDrug Costs
_xtrends
650 0 4 _aDrug Utilization
650 0 4 _aEuropean Union
650 0 4 _aHealth Care Costs
_xtrends
650 0 4 _aHumans
650 0 4 _aMarketing of Health Services
650 0 4 _aPatient Acceptance of Health Care
650 0 4 _aRetrospective Studies
700 1 _aGinard Vicens, Daniel
700 1 _aSampol Mayol, Antonia
700 1 _aTerrasa Pons, Josefa
773 0 _tMedicina clinica
_gvol. 152
_gno. 10
_gp. 411-415
856 4 0 _uhttps://doi.org/10.1016/j.medcli.2018.11.013
_zAvailable from publisher's website
999 _c29293643
_d29293643